Selecting a Contract Development and Manufacturing Organisation (CDMO) for high-potency active pharmaceutical ingredient (HPAPI) small molecule formulation development requires a verification process that is fundamentally more rigorous than for standard compound programmes. The containment infrastructure, operator safety controls and Good […]
Adragos Pharma provides sterile injectable fill-finish Contract Development and Manufacturing Organisation (CDMO) services across three European manufacturing sites in France and Switzerland, supported by visual inspection and packaging capability in Japan. From early-phase clinical batches through to high-volume commercial supply, […]
Pharmaceutical semisolid and liquid manufacturing scale-up is not a larger version of the laboratory batch. It is the disciplined translation of formulation science, process understanding, equipment capability and GMP control into a repeatable commercial process. For development and manufacturing leaders, […]
Commercial sterile injectable manufacturing is not only a production activity. It is a patient safety commitment, a quality system test, and a supply continuity challenge happening at the same time. For pharma and biotech leaders, the most visible consequence of […]
Sterile injectable fill-finish is where CMC either protects patients and timelines, or quietly accumulates risk until it becomes a deviation, an investigation, or a regulatory delay. When we outsource to a European CDMO, the documentation set has to do two […]
When an injectable solution is administered, it bypasses the patient’s normal protective barriers. Skin and the digestive system no longer act as filters. At that point, the primary packaging becomes the barrier. That is the starting point for any sterility […]
Get notified on our latest news.
